Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Total net revenue $ 137,220 $ 117,169
COST OF REVENUE 82,406 78,937
GROSS PROFIT 54,814 38,232
Operating expenses:    
General and administrative 61,549 66,248
Research and development 7,395 7,713
Sales and marketing 16,259 16,299
Restructuring charges 4,684 0
Total operating expenses 89,887 90,260
LOSS FROM OPERATIONS (35,073) (52,028)
Interest (income) expense, net (1,467) 1,301
Other expense (income), net 114 (168)
Loss before taxes (33,720) (53,161)
Income tax benefit (2,925) (3,753)
NET LOSS $ (30,795) $ (49,408)
NET LOSS PER SHARE    
Basic (in dollars per share) $ (0.25) $ (0.40)
Diluted (in dollars per share) $ (0.25) $ (0.40)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    
Basic (in shares) 125,026 123,630
Diluted (in shares) 125,026 123,630
Clinical Services    
Total net revenue $ 114,869 $ 98,791
COST OF REVENUE 67,292 65,267
GROSS PROFIT 47,577 33,524
Pharma Services    
Total net revenue 22,351 18,378
COST OF REVENUE 15,114 13,670
GROSS PROFIT $ 7,237 $ 4,708